dalteparin has been researched along with 2019 Novel Coronavirus Disease in 138 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonischemic CRVO with cystoid macular edema was diagnosed and an intravitreal injection of ranibizumab was performed." | 5.72 | Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case Report. ( Biskup, M; Kal, M; Krupińska, J; Odrobina, D; Płatkowska-Adamska, B, 2022) |
| "The large outbreak of coronavirus disease 2019 (COVID-19) is spreading all over the world rapidly." | 5.62 | Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease. ( Akat, H; Laloglu, F; Orbak, Z, 2021) |
| "In this randomized, open-label, prospective superiority trial involving hospitalized patients with confirmed mild or moderate COVID-19 disease without known thromboembolism, we assigned 230 patients to receive either once-daily oral rivaroxaban (10mg or 15mg) or once-daily subcutaneous enoxaparin (40mg or 60mg) for a median duration of 8 days." | 5.51 | Oral Rivaroxaban in the Prophylaxis of COVID-19 Induced Coagulopathy. ( Chandralekha, S; Kaimaparambil, V; Kumar, D; Lalchandani, J, 2022) |
| "In patients hospitalised with COVID-19 and elevated D-dimer concentration, in-hospital therapeutic anticoagulation with rivaroxaban or enoxaparin followed by rivaroxaban to day 30 did not improve clinical outcomes and increased bleeding compared with prophylactic anticoagulation." | 5.41 | Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. ( Alexander, JH; Armaganijan, L; Avezum, A; Azevedo, LCP; Barbosa, LM; Berwanger, O; Bronhara, B; Canesin, MF; Cavalcanti, AB; Conceição-Souza, GE; Damiani, LP; de Alcântara Chaud, MS; de Aquino Martins, P; de Aveiro Morata, J; de Barros E Silva, PGM; de Faria, LM; de Matos Soeiro, A; de Oliveira Twardowsky, A; de Oliveira, AL; de Souza Dantas, VC; Diaz, DRA; Dracoulakis, MDA; Feitosa-Filho, GS; Fernandes, ACS; Figueiredo, EL; Furtado, RHM; Gazzana, MB; Gebara, OCE; Guimarães, PO; Hernandes, ME; Lima, RGSD; Liporace, IL; Lopes, RD; Macedo, AVS; Machado, FR; Maia, LN; Melro, LMG; Neuenschwander, FC; Nunes, VS; Queiroz, DAR; Ramacciotti, E; Ritt, LEF; Rocha, AT; Rosa, RG; Santos, SV; Tramujas, L; Veiga, VC; Viana, LS, 2021) |
| "A 71-year old gentleman with history of arterial hypertension treated with valsartan presented on was hospitalized at the Infectious Diseases Unit, University of Bologna (Italy) for severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2) and received treatment with hydroxychloroquine 200mg bid (400 mg bid the first day), azithromycin 400 mg qd, thrombotic prophylaxis with enoxaparin 4000 UI qd and Venturi mask oxygen delivering FiO2 of 31%." | 3.96 | Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin. ( Bartoletti, M; Viale, P, 2020) |
| " The aim of our study was to evaluate the clinical impact of venous thromboembolism prophylaxis with fondaparinux versus enoxaparin among 100 hospitalized COVID-19 patients." | 3.96 | Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience. ( Agrusta, F; Amitrano, M; Bellizzi, A; Cardillo, G; Cavalli, A; Di Micco, P; Fontanella, A; Iannuzzo, M; Lodigiani, C; Mangiacapra, S; Russo, V; Sacco, C; Viggiano, GV, 2020) |
| "We report a case of ophthalmic artery occlusion (OAO) in a young patient with COVID-19 infection that was on therapeutic anticoagulation with apixaban for deep venous thrombosis (DVT)." | 3.96 | Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban. ( Biousse, V; Bose, S; Dumitrascu, OM; Lyden, PD; Volod, O; Wang, Y, 2020) |
| "SARS-CoV-2 patients with acute respiratory distress syndrome show elevated fibrinogen activity, high D-dimer levels and maximum amplitude of clot strength." | 3.96 | Thromboelastography clot strength profiles and effect of systemic anticoagulation in COVID-19 acute respiratory distress syndrome: a prospective, observational study. ( Antonelli, M; Biasucci, DG; Bocci, MG; Carelli, S; Consalvo, LM; Cutuli, SL; De Candia, E; Franceschi, F; Gori, C; Grieco, DL; Maviglia, R; Mercurio, G; Montini, L; Nardi, G; Natalini, D; Pisapia, L; Rosenkranz, R, 2020) |
| "The study INHIXACOVID19 was registred on ClinicalTrials." | 3.30 | Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19. ( Bignami, EG; Brambilla, P; Castagna, A; Cosmi, B; Cristini, F; De Stefano, G; Di Perri, G; Drago, F; Fornaro, G; Frattima, S; Giannella, M; Grandone, E; Lupi, M; Mazzaferri, F; Montineri, A; Pan, A; Patacca, A; Romagnoli, A; Rozzini, R; Salvetti, M; Stella, A; Testa, S; Viale, P, 2023) |
| "We aimed to evaluate the effectiveness and safety of enoxaparin compared with UFH when used at their standard/intermediate dosing in COVID-19 patients." | 3.30 | Effectiveness and Safety of Enoxaparin Versus Unfractionated Heparin as Thromboprophylaxis in Hospitalized COVID-19 Patients: Real-World Evidence. ( Abraham, I; Al Saeed, J; Al-Bassam, S; Al-Makki, S; Alamer, A; AlLehaibi, LH; Almulhim, A; Alomar, M; Alrwaili, NR; Alsheef, M; Alsultan, S, 2023) |
| "No DVT developed in COVID-19 patients hospitalized in general wards, independently of enoxaparin dosing used for thromboprophylaxis." | 3.11 | Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial. ( Agostinis, M; Antolini, L; Barberis, D; Birocchi, S; Bonacchini, L; Carioti, G; Cattaneo, M; Gazzaniga, G; Grazia Valsecchi, M; Massaini, G; Merli, M; Morici, N; Podda, G; Saverio Serino, F; Trezzi, M, 2022) |
| " Optimal thromboprophylaxis dosing in high-risk patients is unknown." | 3.01 | Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. ( Agrawal, N; Anderson, VE; Bonaca, M; Cohen, M; Cohoon, KP; Diab, W; Giannis, D; Gianos, E; Goldin, M; Halperin, JL; Hsia, J; Khanijo, S; Lesser, ML; Lewis, PA; Lund, JM; Mignatti, A; Ochani, K; Rahman, H; Sharifova, G; Sison, CP; Spyropoulos, AC; Tafur, A; Wang, J; Weitz, JI, 2021) |
| "A 61-year old patient with ankylosing spondylitis who was on secukinumab therapy for 5 months admitted with newly onset fever and gastrointestinal complaints." | 2.66 | Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review. ( Coskun Benlidayi, I; Guzel, R; Kurtaran, B; Tirasci, E, 2020) |
| " The absorption rate constant of nadroparin was 3." | 1.91 | Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19. ( Borys, M; Cios, W; Czuczwar, M; Okuńska, P; Piwowarczyk, P; Raszewski, G; Szczukocka, M; Wiczling, P, 2023) |
| " Furthermore, of the simulated regimens, targeted anti-Xa levels were most adequately achieved with a dosing regimen of 5700 IU BID." | 1.91 | Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients. ( Endeman, H; Hunfeld, NGM; Kruip, MJHA; Preijers, T; Romano, LGR, 2023) |
| "For discriminating arterial and venous thrombosis, there was no significant difference between the ADA vs." | 1.91 | External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial. ( Chi, G; Cohen, AT; Gibson, CM; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, RD; Loffredo, L; Pignatelli, P; Spagnoli, A; Vestri, A; Violi, F, 2023) |
| "BACKGROUND Coronavirus disease 2019 (COVID-19) has a tremendous impact on the respiratory tract." | 1.72 | A Patient-Tailored Approach to Management of Acute Limb Ischemia in Patients with COVID-19: A Case Series. ( AlGhofili, H; Alhumaid, A; Aljabri, B; Altoijry, A; Iqbal, K, 2022) |
| "Despite standard thromboprophylaxis, venous thrombosis is common in critically ill patients with COVID-19." | 1.72 | [Deep venous thrombosis incidence in patients with COVID-19 acute respiratory distress syndrome, under intermediate dose of chemical thromboprophylaxis]. ( Bonelli, I; Hunter, M; López Saubidet, I; Lurbet, MF; Mandó, F; Parodi, J; Rodríguez, PO, 2022) |
| "COVID-19 associated acute mesenteric ischemia is a complication with high mortality." | 1.72 | Acute Mesenteric Ischemia in COVID-19 While Receiving Prophylactic Enoxaparin. ( Surendran, SA; Sureshkumar, NB, 2022) |
| "Background: Severe progression of coronavirus disease 2019 (COVID-19) causes respiratory failure and critical illness." | 1.72 | HIGH HEPARANASE LEVEL IN SURVIVORS OF COVID-19 - INDICATOR OF VASCULAR AND PULMONARY RECOVERY? ( Adam, EH; Brkic, D; Heinicke, U; Neb, H; Ruskowski, K; Sonntagbauer, M; Talbot, SR; von Knethen, A; Zacharowski, K, 2022) |
| "Nonischemic CRVO with cystoid macular edema was diagnosed and an intravitreal injection of ranibizumab was performed." | 1.72 | Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case Report. ( Biskup, M; Kal, M; Krupińska, J; Odrobina, D; Płatkowska-Adamska, B, 2022) |
| "The data from studies presenting cerebrovascular diseases associated with SARS-Cov-2, which constituted 0." | 1.72 | Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies? ( Ates, O; Dogan, M; Ersoz, E; Hacioglu Kasim, FB; Karaarslan, N; Ozbek, H; Yilmaz, I, 2022) |
| " The inability of PED to adequately protect major circulating blood cells is probably due to enhanced clearance or/and diminished bioavailability of enoxaparin during COVID." | 1.62 | Enoxaparin dose impacts blood cell phenotypes during mild SARS-CoV-2 infection: the observational single-center study. ( Buryachkovskaya, L; Docenko, J; Ermishkin, V; Lomakin, N; Melkumyants, A; Serebruany, V, 2021) |
| "Penile thrombosis has not been reported as a thrombotic complication of SARS-CoV-2 infection with hypercoagulability." | 1.62 | Priapism in a patient with coronavirus disease 2019 (COVID-19). ( Abbad, S; Chebbi, A; Lamamri, M; Legriel, S; Mamane, J; Munuzzolini, M; Sarfati, F, 2021) |
| "The large outbreak of coronavirus disease 2019 (COVID-19) is spreading all over the world rapidly." | 1.62 | Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease. ( Akat, H; Laloglu, F; Orbak, Z, 2021) |
| "BACKGROUND Pandemic coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)." | 1.62 | Superficial Cerebral Venous Thrombosis and Intracerebral Hematoma in a 48-Year-Old Man with SARS-CoV-2 Infection: A Case Report. ( Bains, SS; Cardoso, ER; Farkas, J; Robison, B, 2021) |
| " At 21 days, the incidence rate of death and clinical deterioration were lower in patients on higher doses than in those on the standard dosage (hazard ratio 0." | 1.62 | Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19. ( Abbattista, M; Aliberti, S; Artoni, A; Blasi, F; Carrafiello, G; Ciavarella, A; De Zan, V; Folli, C; Gori, A; Grasselli, G; Ierardi, AM; Martinelli, I; Monzani, V; Panigada, M; Peyvandi, F, 2021) |
| " Accordingly, recent data suggested a beneficial role of low molecular weight heparin (LMWH), but the optimal dosage of this treatment is unknown." | 1.62 | Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19. ( Aimaretti, G; Avanzi, GC; Azzolina, D; Bellan, M; Cantaluppi, V; Capponi, A; Castello, LM; Cipollone, F; Colombo, C; Corte, FD; D'Ardes, D; Foglietta, M; Gallina, S; Grisafi, L; Hayden, E; Krengli, M; Lio, V; Malerba, M; Mennuni, MG; Patti, G; Petrilli, I; Pierdomenico, SD; Pirisi, M; Renda, G; Rognoni, A; Sainaghi, PP; Savoia, P; Spinoni, E; Zeppegno, P, 2021) |
| "Coronavirus is a source of deep venous thrombosis (DVT) due to complications such as over-coagulation, blood stasis, and endothelial damage." | 1.62 | Ovarian vein thrombosis after coronavirus disease (COVID-19) mimicking acute abdomen: two case reports. ( Abdeladim, S; Bensahi, I; Elouarradi, A; Fatimazahra, M; Harras, ME; Kassimi, M; Oualim, S; Sabry, M, 2021) |
| "To develop a pharmacokinetic model of enoxaparin to predict the time-exposure profiles of various thromboprophylactic regimens in COVID-19 ICU-patients." | 1.62 | Pharmacokinetics of enoxaparin in COVID-19 critically ill patients. ( Bauters, A; Caplan, M; Delavenne, X; Dupont, A; Goutay, J; Jean, L; Lanoiselée, J; Levy, L; Poissy, J; Susen, S; Zufferey, PJ, 2021) |
| " An antithrombotic prophylaxis at low dosage was immediately started, then increased at prophylactic dosage." | 1.56 | How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report. ( Campello, E; Pasca, S; Simioni, P; Spiezia, L; Vettor, R; Zanon, E, 2020) |
| "Acute pulmonary embolism and coronavirus disease were diagnosed." | 1.56 | COVID-19 and Acute Pulmonary Embolism in Postpartum Patient. ( Boogar, SS; Khodamoradi, Z; Kouhi, P; Shirazi, FKH, 2020) |
| "Key words: Coronavirus disease 2019 (COVID-19), Meningoencephalitis, Pneumonia." | 1.56 | A Case of 45-Year Man Who Succumbed to Coronavirus Disease 2019 (COVID-19). ( Khan, MA, 2020) |
| "We present a late presentation of saddle pulmonary embolism and thrombus-in-transit straddle the patent foramen on patient who successfully recovered from severe acute respiratory syndrome coronavirus-2 (COVID-19) pneumonia." | 1.56 | Saddle pulmonary embolism and thrombus-in-transit straddling the patent foramen ovale 28 days after COVID symptom onset. ( Fontes, JD; Fujikura, K; Taub, CC, 2020) |
| "A chest CT scan showed an acute type B aortic dissection (ATBAD) and bilateral lung involvement with ground-glass opacity, compatible with interstitial pneumonia." | 1.56 | An infection-oriented approach for thoracic endovascular aortic repair in a SARS-CoV-2 positive patient. A case report. ( Ferrari, SA; Muzzarelli, L; Piconi, S; Rossi, G; Sommaruga, S, 2020) |
| " The purpose of the study was to evaluate the association between initial dosing strategy of thromboprophylaxis in critically ill COVID-19 patients and the risk of death, thromboembolism, and bleeding." | 1.56 | Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. ( Cronhjort, M; Dahlberg, M; Everhov, ÅH; Grip, J; Günther, M; Hollenberg, J; Järnbert-Pettersson, H; Jonmarker, S; Litorell, J; Schandl, A; Söderberg, M; Stackelberg, O, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 138 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eck, RJ | 1 |
| van de Leur, JJCM | 1 |
| Wiersema, R | 1 |
| Cox, EGM | 1 |
| Bult, W | 1 |
| Spanjersberg, AJ | 1 |
| van der Horst, ICC | 1 |
| Lukens, MV | 1 |
| Gans, ROB | 1 |
| Meijer, K | 1 |
| Keus, F | 1 |
| Romano, LGR | 2 |
| Hunfeld, NGM | 2 |
| Kruip, MJHA | 2 |
| Endeman, H | 2 |
| Preijers, T | 2 |
| Piwowarczyk, P | 1 |
| Szczukocka, M | 1 |
| Cios, W | 1 |
| Okuńska, P | 1 |
| Raszewski, G | 1 |
| Borys, M | 1 |
| Wiczling, P | 1 |
| Czuczwar, M | 1 |
| Brüggemann, R | 1 |
| Gietema, H | 1 |
| Jallah, B | 1 |
| Ten Cate, H | 1 |
| Stehouwer, C | 1 |
| Spaetgens, B | 1 |
| Trunfio, M | 1 |
| Salvador, E | 1 |
| Cabodi, D | 1 |
| Marinaro, L | 1 |
| Alcantarini, C | 1 |
| Gaviraghi, A | 1 |
| Trentalange, A | 1 |
| Lipani, F | 1 |
| Sciascia, S | 1 |
| Roccatello, D | 1 |
| Bonora, S | 1 |
| Di Perri, G | 2 |
| Calcagno, A | 1 |
| Marcos-Jubilar, M | 1 |
| Carmona-Torre, F | 1 |
| Vidal, R | 1 |
| Ruiz-Artacho, P | 1 |
| Filella, D | 1 |
| Carbonell, C | 1 |
| Jiménez-Yuste, V | 1 |
| Schwartz, J | 1 |
| Llamas, P | 1 |
| Alegre, F | 1 |
| Sádaba, B | 1 |
| Núñez-Córdoba, J | 1 |
| Yuste, JR | 1 |
| Fernández-García, J | 1 |
| Lecumberri, R | 1 |
| Varona, JF | 1 |
| Núñez, E | 1 |
| Fernández Félix, BM | 1 |
| Castellano Vázquez, JM | 1 |
| Cubillo, A | 1 |
| Lozano, R | 1 |
| Franco, ME | 1 |
| Doello, K | 1 |
| Amezcua, V | 1 |
| Sargin Altunok, E | 1 |
| Satici, C | 1 |
| Dinc, V | 1 |
| Kamat, S | 2 |
| Alkan, M | 1 |
| Demirkol, MA | 1 |
| Toprak, ID | 1 |
| Kostek, ME | 1 |
| Yazla, S | 1 |
| Esatoglu, SN | 1 |
| Spyropoulos, AC | 3 |
| Goldin, M | 2 |
| Giannis, D | 2 |
| Diab, W | 2 |
| Wang, J | 2 |
| Khanijo, S | 2 |
| Mignatti, A | 2 |
| Gianos, E | 2 |
| Cohen, M | 2 |
| Sharifova, G | 2 |
| Lund, JM | 2 |
| Tafur, A | 2 |
| Lewis, PA | 2 |
| Cohoon, KP | 1 |
| Rahman, H | 2 |
| Sison, CP | 2 |
| Lesser, ML | 2 |
| Ochani, K | 2 |
| Agrawal, N | 1 |
| Hsia, J | 1 |
| Anderson, VE | 2 |
| Bonaca, M | 2 |
| Halperin, JL | 2 |
| Weitz, JI | 2 |
| Marini, CP | 1 |
| Lewis, E | 1 |
| Petrone, P | 1 |
| Zenilman, A | 1 |
| Lu, Z | 1 |
| Rivera, A | 1 |
| McNelis, J | 1 |
| Faour, WH | 1 |
| Choaib, A | 1 |
| Issa, E | 1 |
| Choueiry, FE | 1 |
| Shbaklo, K | 1 |
| Alhajj, M | 1 |
| Sawaya, RT | 1 |
| Harhous, Z | 1 |
| Alefishat, E | 1 |
| Nader, M | 1 |
| Daye, M | 1 |
| Oltulu, P | 1 |
| Buryachkovskaya, L | 1 |
| Lomakin, N | 1 |
| Melkumyants, A | 1 |
| Docenko, J | 1 |
| Ermishkin, V | 1 |
| Serebruany, V | 1 |
| Morici, N | 2 |
| Podda, G | 1 |
| Birocchi, S | 1 |
| Bonacchini, L | 1 |
| Merli, M | 1 |
| Trezzi, M | 1 |
| Massaini, G | 1 |
| Agostinis, M | 1 |
| Carioti, G | 1 |
| Saverio Serino, F | 1 |
| Gazzaniga, G | 1 |
| Barberis, D | 1 |
| Antolini, L | 1 |
| Grazia Valsecchi, M | 1 |
| Cattaneo, M | 2 |
| Di Micco, P | 3 |
| Imbalzano, E | 1 |
| Russo, V | 3 |
| Attena, E | 1 |
| Mandaliti, V | 1 |
| Orlando, L | 1 |
| Lombardi, M | 1 |
| Di Micco, G | 1 |
| Camporese, G | 1 |
| Annunziata, S | 1 |
| Piccinocchi, G | 1 |
| Pacelli, W | 1 |
| Del Guercio, M | 1 |
| Szydełko-Paśko, U | 1 |
| Przeździecka-Dołyk, J | 1 |
| Kręcicka, J | 1 |
| Małecki, R | 1 |
| Misiuk-Hojło, M | 1 |
| Turno-Kręcicka, A | 1 |
| Alhumaid, A | 1 |
| Altoijry, A | 1 |
| Aljabri, B | 1 |
| Iqbal, K | 1 |
| AlGhofili, H | 1 |
| Keskin, H | 1 |
| Keskin, F | 1 |
| Yildirim, E | 1 |
| Saritas, S | 1 |
| Polat, G | 1 |
| Colak, A | 1 |
| Laloglu, F | 2 |
| Guler, MA | 1 |
| Ozay, M | 1 |
| Alp, H | 1 |
| Farkouh, ME | 2 |
| Stone, GW | 4 |
| Lala, A | 2 |
| Bagiella, E | 1 |
| Moreno, PR | 2 |
| Nadkarni, GN | 2 |
| Ben-Yehuda, O | 1 |
| Granada, JF | 1 |
| Dressler, O | 2 |
| Tinuoye, EO | 1 |
| Granada, C | 2 |
| Bustamante, J | 2 |
| Peyra, C | 2 |
| Godoy, LC | 2 |
| Palacios, IF | 2 |
| Fuster, V | 2 |
| Zaragoza-Huesca, D | 1 |
| Martínez-Cortés, C | 1 |
| Banegas-Luna, AJ | 1 |
| Pérez-Garrido, A | 1 |
| Vegara-Meseguer, JM | 1 |
| Peñas-Martínez, J | 1 |
| Rodenas, MC | 1 |
| Espín, S | 1 |
| Pérez-Sánchez, H | 1 |
| Martínez-Martínez, I | 1 |
| Calabretta, F | 1 |
| Preti, PS | 1 |
| Russo, M | 2 |
| Klersy, C | 1 |
| Di Sabatino, A | 1 |
| Hunter, M | 1 |
| Lurbet, MF | 1 |
| Parodi, J | 1 |
| Mandó, F | 1 |
| Bonelli, I | 1 |
| Rodríguez, PO | 1 |
| López Saubidet, I | 1 |
| Elikowski, W | 1 |
| Fertała, N | 1 |
| Zawodna-Marszałek, M | 1 |
| Karoń, J | 1 |
| Skrzywanek, P | 1 |
| Mozer-Lisewska, I | 1 |
| Szczęśniewski, P | 1 |
| Łazowski, S | 1 |
| Żytkiewicz, M | 1 |
| Kumar, D | 1 |
| Kaimaparambil, V | 1 |
| Chandralekha, S | 1 |
| Lalchandani, J | 1 |
| Sochet, AA | 1 |
| Morrison, JM | 1 |
| Jaffray, J | 1 |
| Godiwala, N | 1 |
| Wilson, HP | 1 |
| Thornburg, CD | 1 |
| Bhat, RV | 1 |
| Zia, A | 1 |
| Lawrence, C | 1 |
| Kudchadkar, SR | 1 |
| Hamblin, F | 1 |
| Russell, CJ | 1 |
| Streiff, MB | 1 |
| Amankwah, EK | 1 |
| Goldenberg, NA | 1 |
| Porres-Aguilar, M | 1 |
| Anaya-Ayala, JE | 1 |
| Barco, S | 5 |
| Voci, D | 4 |
| Held, U | 5 |
| Sebastian, T | 5 |
| Bingisser, R | 5 |
| Colucci, G | 5 |
| Duerschmied, D | 4 |
| Frenk, A | 2 |
| Gerber, B | 5 |
| Götschi, A | 4 |
| Konstantinides, SV | 4 |
| Mach, F | 5 |
| Robert-Ebadi, H | 4 |
| Rosemann, T | 5 |
| Simon, NR | 4 |
| Spechbach, H | 1 |
| Spirk, D | 4 |
| Stortecky, S | 5 |
| Vaisnora, L | 4 |
| Righini, M | 6 |
| Kucher, N | 5 |
| Cools, F | 1 |
| Virdone, S | 1 |
| Sawhney, J | 1 |
| Lopes, RD | 3 |
| Jacobson, B | 1 |
| Arcelus, JI | 1 |
| Hobbs, FDR | 1 |
| Gibbs, H | 1 |
| Himmelreich, JCL | 1 |
| MacCallum, P | 1 |
| Schellong, S | 1 |
| Haas, S | 1 |
| Turpie, AGG | 1 |
| Ageno, W | 1 |
| Rocha, AT | 2 |
| Kayani, G | 1 |
| Pieper, K | 1 |
| Kakkar, AK | 1 |
| Ates, O | 1 |
| Yilmaz, I | 1 |
| Karaarslan, N | 1 |
| Ersoz, E | 1 |
| Hacioglu Kasim, FB | 1 |
| Dogan, M | 1 |
| Ozbek, H | 1 |
| Mohamed, AS | 1 |
| Ahmad, HM | 1 |
| Abdul-Raheem, ASA | 1 |
| Kamel, FMM | 1 |
| Khames, A | 1 |
| Mady, AF | 1 |
| AlLehaibi, LH | 1 |
| Alomar, M | 1 |
| Almulhim, A | 1 |
| Al-Makki, S | 1 |
| Alrwaili, NR | 1 |
| Al-Bassam, S | 1 |
| Alsultan, S | 1 |
| Al Saeed, J | 1 |
| Alsheef, M | 1 |
| Abraham, I | 1 |
| Alamer, A | 1 |
| Araldi, RP | 1 |
| Prezoto, BC | 1 |
| Gonzaga, V | 1 |
| Policiquio, B | 1 |
| Mendes, TB | 1 |
| D'Amélio, F | 1 |
| Vigerelli, H | 1 |
| Viana, M | 1 |
| Valverde, CW | 1 |
| Pagani, E | 1 |
| Kerkis, I | 1 |
| Deokar, K | 1 |
| Kaliya, M | 1 |
| Vachhani, K | 1 |
| Singhal, S | 1 |
| Parekh, A | 1 |
| Schiavina, M | 1 |
| Pontoriero, L | 1 |
| Tagliaferro, G | 1 |
| Pierattelli, R | 1 |
| Felli, IC | 1 |
| Płatkowska-Adamska, B | 1 |
| Kal, M | 1 |
| Krupińska, J | 1 |
| Biskup, M | 1 |
| Odrobina, D | 1 |
| Eder, J | 1 |
| Bermejo-Jambrina, M | 1 |
| Vlaming, KE | 1 |
| Kaptein, TM | 1 |
| Zaderer, V | 1 |
| Kemper, EM | 1 |
| Wilflingseder, D | 1 |
| Reitsma, S | 1 |
| de Bree, GJ | 1 |
| Cohn, DM | 1 |
| Geijtenbeek, TBH | 1 |
| Fumagalli, RM | 3 |
| Hasse, B | 3 |
| Keller, DI | 3 |
| Rampini, SK | 3 |
| Roth-Zetzsche, S | 3 |
| Albisinni, R | 2 |
| Vitrone, M | 2 |
| Ursi, MP | 2 |
| Spiezia, S | 2 |
| Salemme, A | 2 |
| Florio, LL | 2 |
| Boccia, F | 2 |
| Iossa, D | 2 |
| Zampino, R | 2 |
| Atripaldi, L | 2 |
| Squillante, F | 2 |
| Maturo, N | 2 |
| Fraganza, F | 2 |
| Severino, S | 2 |
| Punzi, R | 2 |
| Fiorentino, G | 2 |
| Masjedi, M | 1 |
| Azadikhah, S | 1 |
| Zand, F | 1 |
| Asmarian, N | 1 |
| Sabetian, G | 1 |
| Ostovan, M | 1 |
| Naderi-Boldaji, V | 1 |
| Neb, H | 1 |
| Talbot, SR | 1 |
| Ruskowski, K | 1 |
| Brkic, D | 1 |
| Sonntagbauer, M | 1 |
| Adam, EH | 1 |
| von Knethen, A | 1 |
| Zacharowski, K | 1 |
| Heinicke, U | 1 |
| Chi, G | 1 |
| Violi, F | 1 |
| Pignatelli, P | 1 |
| Vestri, A | 1 |
| Spagnoli, A | 1 |
| Loffredo, L | 1 |
| Hernandez, AF | 1 |
| Hull, RD | 1 |
| Cohen, AT | 1 |
| Harrington, RA | 1 |
| Goldhaber, SZ | 4 |
| Gibson, CM | 1 |
| Sureshkumar, NB | 1 |
| Surendran, SA | 1 |
| Afsharirad, B | 1 |
| Entezari-Maleki, T | 1 |
| Tinuoye, E | 1 |
| Goodman, SG | 1 |
| Esper, RB | 1 |
| Abizaid, A | 1 |
| Varade, D | 1 |
| Betancur, JF | 1 |
| Ricalde, A | 1 |
| Payro, G | 1 |
| Castellano, JM | 1 |
| Hung, IFN | 1 |
| Giustino, G | 1 |
| Feinman, J | 1 |
| Camaj, A | 1 |
| Bienstock, SW | 1 |
| Furtado, RHM | 3 |
| Contreras, J | 1 |
| Owen, R | 1 |
| Bhatt, DL | 1 |
| Pocock, SJ | 1 |
| Bermúdez-Ruiz, MDC | 1 |
| Vilar Sánchez, I | 1 |
| Aparicio Pérez, C | 1 |
| Carmona Flores, R | 1 |
| Rodríguez-Gómez, J | 1 |
| de la Fuente-Martos, C | 1 |
| Ehsan, M | 1 |
| Jafar, U | 1 |
| Butt, M | 1 |
| Naveed, A | 1 |
| Umer, M | 1 |
| Ayyan, M | 1 |
| Mustafa, B | 1 |
| Awan, RU | 1 |
| Iqbal, Z | 1 |
| Sadaf, S | 1 |
| Cosmi, B | 1 |
| Giannella, M | 1 |
| Fornaro, G | 1 |
| Cristini, F | 1 |
| Patacca, A | 1 |
| Castagna, A | 1 |
| Mazzaferri, F | 1 |
| Testa, S | 1 |
| Pan, A | 1 |
| Lupi, M | 1 |
| Brambilla, P | 1 |
| Montineri, A | 1 |
| Frattima, S | 1 |
| Bignami, EG | 1 |
| Salvetti, M | 1 |
| De Stefano, G | 1 |
| Grandone, E | 1 |
| Rozzini, R | 1 |
| Stella, A | 1 |
| Romagnoli, A | 1 |
| Drago, F | 1 |
| Viale, P | 2 |
| Griffin, DO | 2 |
| Jensen, A | 1 |
| Khan, M | 1 |
| Chin, J | 1 |
| Chin, K | 1 |
| Saad, J | 1 |
| Parnell, R | 1 |
| Awwad, C | 1 |
| Patel, D | 1 |
| Khodamoradi, Z | 1 |
| Boogar, SS | 1 |
| Shirazi, FKH | 1 |
| Kouhi, P | 1 |
| Artifoni, M | 1 |
| Danic, G | 1 |
| Gautier, G | 1 |
| Gicquel, P | 1 |
| Boutoille, D | 1 |
| Raffi, F | 1 |
| Néel, A | 1 |
| Lecomte, R | 1 |
| Marietta, M | 1 |
| Tripodi, A | 1 |
| Alay, H | 1 |
| Can, FK | 1 |
| Gözgeç, E | 1 |
| Akel, T | 1 |
| Qaqa, F | 1 |
| Abuarqoub, A | 1 |
| Shamoon, F | 1 |
| Bartoletti, M | 1 |
| Mattioli, M | 2 |
| Fustini, E | 1 |
| Gennarini, S | 1 |
| Valente-Acosta, B | 1 |
| Moreno-Sanchez, F | 1 |
| Fueyo-Rodriguez, O | 1 |
| Palomar-Lever, A | 1 |
| Coskun Benlidayi, I | 1 |
| Kurtaran, B | 1 |
| Tirasci, E | 1 |
| Guzel, R | 1 |
| Sierra-Hidalgo, F | 1 |
| Muñoz-Rivas, N | 1 |
| Torres Rubio, P | 1 |
| Chao, K | 1 |
| Villanova Martínez, M | 1 |
| Arranz García, P | 1 |
| Martínez-Acebes, E | 1 |
| La Mura, V | 1 |
| Artoni, A | 2 |
| Martinelli, I | 2 |
| Rossio, R | 1 |
| Gualtierotti, R | 1 |
| Ghigliazza, G | 1 |
| Fusco, S | 1 |
| Ierardi, AM | 2 |
| Andrisani, MC | 1 |
| Carrafiello, G | 2 |
| Peyvandi, F | 2 |
| Santoliquido, A | 1 |
| Porfidia, A | 1 |
| Nesci, A | 1 |
| De Matteis, G | 1 |
| Marrone, G | 1 |
| Porceddu, E | 1 |
| Cammà, G | 1 |
| Giarretta, I | 1 |
| Fantoni, M | 1 |
| Landi, F | 1 |
| Gasbarrini, A | 1 |
| Pola, R | 1 |
| D'Alfonso, ME | 1 |
| Lo Monaco, MR | 1 |
| Massabeti, R | 1 |
| Cipriani, MS | 1 |
| Valenti, I | 1 |
| Zanon, E | 1 |
| Pasca, S | 1 |
| Campello, E | 1 |
| Spiezia, L | 1 |
| Vettor, R | 1 |
| Simioni, P | 1 |
| Dumitrascu, OM | 1 |
| Volod, O | 1 |
| Bose, S | 1 |
| Wang, Y | 1 |
| Biousse, V | 1 |
| Lyden, PD | 1 |
| Trimaille, A | 1 |
| Curtiaud, A | 1 |
| Marchandot, B | 1 |
| Matsushita, K | 1 |
| Sato, C | 1 |
| Leonard-Lorant, I | 1 |
| Sattler, L | 2 |
| Grunebaum, L | 2 |
| Ohana, M | 1 |
| Von Hunolstein, JJ | 1 |
| Andres, E | 1 |
| Goichot, B | 1 |
| Danion, F | 1 |
| Kaeuffer, C | 1 |
| Poindron, V | 1 |
| Ohlmann, P | 1 |
| Jesel, L | 1 |
| Morel, O | 1 |
| Moll, M | 1 |
| Zon, RL | 1 |
| Sylvester, KW | 1 |
| Chen, EC | 1 |
| Cheng, V | 1 |
| Connell, NT | 1 |
| Fredenburgh, LE | 1 |
| Baron, RM | 1 |
| Cho, MH | 1 |
| Woolley, AE | 1 |
| Connors, JM | 1 |
| Abrams, RMC | 1 |
| Kim, BD | 1 |
| Markantone, DM | 1 |
| Reilly, K | 1 |
| Paniz-Mondolfi, AE | 1 |
| Gitman, MR | 1 |
| Choo, SY | 1 |
| Tse, W | 1 |
| Robinson-Papp, J | 1 |
| Khan, MA | 2 |
| Gurkan, O | 1 |
| Yilmaz, A | 1 |
| Cengel, F | 1 |
| Altunok, ES | 1 |
| Ekin, EE | 1 |
| Lal, S | 1 |
| Hashmi, J | 1 |
| Lamamri, M | 1 |
| Chebbi, A | 1 |
| Mamane, J | 1 |
| Abbad, S | 1 |
| Munuzzolini, M | 1 |
| Sarfati, F | 1 |
| Legriel, S | 1 |
| Fujikura, K | 1 |
| Fontes, JD | 1 |
| Taub, CC | 1 |
| Whittemore, P | 1 |
| Macfarlane, L | 1 |
| Herbert, A | 1 |
| Farrant, J | 1 |
| Ferguson, K | 1 |
| Quail, N | 1 |
| Kewin, P | 1 |
| Blyth, KG | 1 |
| Kewan, T | 1 |
| Almhana, F | 1 |
| Schwartzman, L | 1 |
| Daw, H | 1 |
| Haddad, A | 1 |
| Benfaremo, D | 1 |
| Mancini, M | 1 |
| Mucci, L | 1 |
| Mainquà, P | 1 |
| Polenta, A | 1 |
| Baldini, PM | 1 |
| Fulgenzi, F | 1 |
| Dennetta, D | 1 |
| Bedetta, S | 1 |
| Gasperoni, L | 1 |
| Caraffa, A | 1 |
| Frausini, G | 1 |
| Feugeas, O | 1 |
| Hager, C | 1 |
| Desprez, D | 1 |
| Del Castillo, R | 1 |
| Martinez, D | 1 |
| Sarria, GJ | 1 |
| Pinillos, L | 1 |
| Garcia, B | 1 |
| Castillo, L | 1 |
| Carhuactocto, A | 1 |
| Giordano, FA | 1 |
| Sarria, GR | 1 |
| Rossi, G | 1 |
| Ferrari, SA | 1 |
| Sommaruga, S | 1 |
| Muzzarelli, L | 1 |
| Piconi, S | 1 |
| Mazzolai, L | 1 |
| Spescha, R | 1 |
| Windecker, S | 1 |
| Lazar, M | 1 |
| Tomey, MI | 1 |
| Ghia, S | 1 |
| Katz, D | 1 |
| Derr, K | 1 |
| Narula, J | 1 |
| Bhatt, HV | 1 |
| Carmo Filho, A | 1 |
| Cunha, BDS | 1 |
| Lemos, ACB | 1 |
| do Espírito Santo, DA | 1 |
| Salvetti, MC | 1 |
| Gilio, RN | 1 |
| Agra, LB | 1 |
| Pazin-Filho, A | 1 |
| Miranda, CH | 1 |
| Bikdeli, B | 3 |
| Talasaz, AH | 3 |
| Rashidi, F | 3 |
| Sharif-Kashani, B | 3 |
| Farrokhpour, M | 3 |
| Bakhshandeh, H | 3 |
| Sezavar, H | 1 |
| Dabbagh, A | 3 |
| Beigmohammadi, MT | 3 |
| Payandemehr, P | 3 |
| Yadollahzadeh, M | 3 |
| Riahi, T | 3 |
| Khalili, H | 3 |
| Jamalkhani, S | 3 |
| Rezaeifar, P | 3 |
| Abedini, A | 3 |
| Lookzadeh, S | 3 |
| Shahmirzaei, S | 3 |
| Tahamtan, O | 3 |
| Matin, S | 3 |
| Amin, A | 3 |
| Parhizgar, SE | 3 |
| Jimenez, D | 3 |
| Gupta, A | 3 |
| Madhavan, MV | 3 |
| Parikh, SA | 3 |
| Monreal, M | 3 |
| Hadavand, N | 3 |
| Hajighasemi, A | 3 |
| Maleki, M | 3 |
| Sadeghian, S | 3 |
| Mohebbi, B | 3 |
| Piazza, G | 3 |
| Kirtane, AJ | 3 |
| Lip, GYH | 3 |
| Krumholz, HM | 3 |
| Sadeghipour, P | 5 |
| Prandoni, P | 1 |
| Cattelan, AM | 1 |
| Carrozzi, L | 1 |
| Leone, L | 1 |
| Filippi, L | 1 |
| De Gaudenzi, E | 1 |
| Villalta, S | 1 |
| Pesavento, R | 1 |
| Nachega, JB | 1 |
| Ishoso, DK | 1 |
| Otokoye, JO | 1 |
| Hermans, MP | 1 |
| Machekano, RN | 1 |
| Sam-Agudu, NA | 1 |
| Bongo-Pasi Nswe, C | 1 |
| Mbala-Kingebeni, P | 1 |
| Madinga, JN | 1 |
| Mukendi, S | 1 |
| Kolié, MC | 1 |
| Nkwembe, EN | 1 |
| Mbuyi, GM | 1 |
| Nsio, JM | 1 |
| Mukeba Tshialala, D | 1 |
| Tshiasuma Pipo, M | 1 |
| Ahuka-Mundeke, S | 1 |
| Muyembe-Tamfum, JJ | 1 |
| Mofenson, L | 1 |
| Smith, G | 1 |
| Mills, EJ | 1 |
| Mellors, JW | 1 |
| Zumla, A | 1 |
| Mavungu Landu, DJ | 1 |
| Kayembe, JM | 1 |
| Cardillo, G | 1 |
| Viggiano, GV | 1 |
| Mangiacapra, S | 1 |
| Cavalli, A | 1 |
| Fontanella, A | 1 |
| Agrusta, F | 1 |
| Bellizzi, A | 1 |
| Amitrano, M | 1 |
| Iannuzzo, M | 1 |
| Sacco, C | 1 |
| Lodigiani, C | 2 |
| Belcaro, G | 1 |
| Corsi, M | 1 |
| Agus, GB | 1 |
| Cesarone, MR | 1 |
| Cornelli, U | 1 |
| Cotellese, R | 1 |
| Feragalli, B | 1 |
| Hu, S | 1 |
| Atallah, B | 1 |
| Sadik, ZG | 1 |
| Salem, N | 1 |
| El Nekidy, WS | 1 |
| Almahmeed, W | 1 |
| Park, WM | 1 |
| Cherfan, A | 1 |
| Hamed, F | 1 |
| Mallat, J | 1 |
| Bhatt, H | 1 |
| Singh, S | 1 |
| Weingarten, M | 2 |
| Abittan, B | 1 |
| Rivera-Oyola, R | 1 |
| Abittan, AI | 1 |
| Lebwohl, M | 1 |
| Orbak, Z | 1 |
| Akat, H | 1 |
| D'Ardes, D | 2 |
| Carrarini, C | 1 |
| Dono, F | 1 |
| Speranza, R | 1 |
| Digiovanni, A | 1 |
| Martinotti, G | 1 |
| Di Iorio, A | 1 |
| Onofrj, M | 1 |
| Cipollone, F | 2 |
| Bonanni, L | 1 |
| Billett, HH | 1 |
| Reyes-Gil, M | 1 |
| Szymanski, J | 1 |
| Ikemura, K | 1 |
| Stahl, LR | 1 |
| Lo, Y | 1 |
| Rahman, S | 1 |
| Gonzalez-Lugo, JD | 1 |
| Kushnir, M | 1 |
| Barouqa, M | 1 |
| Golestaneh, L | 1 |
| Bellin, E | 1 |
| Boari, GEM | 1 |
| Chiarini, G | 1 |
| Bonetti, S | 1 |
| Malerba, P | 1 |
| Bianco, G | 1 |
| Faustini, C | 1 |
| Braglia-Orlandini, F | 1 |
| Turini, D | 1 |
| Guarinoni, V | 1 |
| Saottini, M | 1 |
| Viola, S | 1 |
| Ferrari-Toninelli, G | 1 |
| Pasini, G | 1 |
| Mascadri, C | 1 |
| Bonzi, B | 1 |
| Desenzani, P | 1 |
| Tusi, C | 1 |
| Zanotti, E | 1 |
| Nardin, M | 1 |
| Rizzoni, D | 1 |
| Chérrez-Ojeda, I | 1 |
| Vanegas, E | 1 |
| Felix, M | 1 |
| Demir, NA | 1 |
| Basturk, A | 1 |
| Ural, O | 1 |
| Sumer, S | 1 |
| Erdogdu, B | 1 |
| Kiratli, HE | 1 |
| Celik, JB | 1 |
| Koplay, M | 1 |
| Vatansev, H | 1 |
| Hamadé, A | 1 |
| Woehl, B | 1 |
| Harzallah, I | 1 |
| Talbot, M | 1 |
| Tousch, J | 1 |
| Jambert, L | 1 |
| Bocci, MG | 1 |
| Maviglia, R | 1 |
| Consalvo, LM | 1 |
| Grieco, DL | 1 |
| Montini, L | 1 |
| Mercurio, G | 1 |
| Nardi, G | 1 |
| Pisapia, L | 1 |
| Cutuli, SL | 1 |
| Biasucci, DG | 1 |
| Gori, C | 1 |
| Rosenkranz, R | 1 |
| De Candia, E | 1 |
| Carelli, S | 1 |
| Natalini, D | 1 |
| Antonelli, M | 1 |
| Franceschi, F | 1 |
| Cardoso, ER | 1 |
| Bains, SS | 1 |
| Robison, B | 1 |
| Farkas, J | 1 |
| Ciavarella, A | 1 |
| Abbattista, M | 1 |
| Aliberti, S | 1 |
| De Zan, V | 1 |
| Folli, C | 1 |
| Panigada, M | 1 |
| Gori, A | 1 |
| Monzani, V | 1 |
| Grasselli, G | 1 |
| Blasi, F | 1 |
| Audley, GG | 1 |
| Frankenfeld, P | 1 |
| Dlamini, S | 1 |
| Raubenheimer, P | 1 |
| Hoare, J | 1 |
| Cairncross, L | 1 |
| Van den Berg, R | 1 |
| Gule, MV | 1 |
| Calligaro, G | 1 |
| Arachchillage, DRJ | 1 |
| Shi, C | 1 |
| Saliu, D | 1 |
| Kozman, P | 1 |
| Mi, E | 1 |
| Buti, N | 1 |
| Kashef, E | 1 |
| Copley, SJ | 1 |
| Gomez, C | 1 |
| Leonard, R | 1 |
| Aziz, R | 1 |
| Shlebak, AA | 1 |
| Laffan, M | 1 |
| Sukhdeo, S | 1 |
| Negroponte, E | 1 |
| Rajasekhar, H | 1 |
| Gaur, S | 1 |
| Horton, DB | 1 |
| Malhotra, A | 1 |
| Moorthy, LN | 1 |
| Cuker, A | 1 |
| Tseng, EK | 1 |
| Nieuwlaat, R | 1 |
| Angchaisuksiri, P | 1 |
| Blair, C | 1 |
| Dane, K | 1 |
| Davila, J | 1 |
| DeSancho, MT | 1 |
| Diuguid, D | 1 |
| Kahn, SR | 1 |
| Klok, FA | 1 |
| Lee, AI | 1 |
| Neumann, I | 1 |
| Pai, A | 1 |
| Pai, M | 1 |
| Sanfilippo, KM | 1 |
| Siegal, D | 1 |
| Skara, M | 1 |
| Touri, K | 1 |
| Akl, EA | 1 |
| Bou Akl, I | 1 |
| Boulos, M | 1 |
| Brignardello-Petersen, R | 1 |
| Charide, R | 1 |
| Chan, M | 1 |
| Dearness, K | 1 |
| Darzi, AJ | 1 |
| Kolb, P | 1 |
| Colunga-Lozano, LE | 1 |
| Mansour, R | 1 |
| Morgano, GP | 1 |
| Morsi, RZ | 1 |
| Noori, A | 1 |
| Piggott, T | 1 |
| Qiu, Y | 1 |
| Roldan, Y | 1 |
| Schünemann, F | 1 |
| Stevens, A | 1 |
| Solo, K | 1 |
| Ventresca, M | 1 |
| Wiercioch, W | 1 |
| Mustafa, RA | 1 |
| Schünemann, HJ | 1 |
| Rentsch, CT | 1 |
| Beckman, JA | 1 |
| Tomlinson, L | 1 |
| Gellad, WF | 1 |
| Alcorn, C | 1 |
| Kidwai-Khan, F | 1 |
| Skanderson, M | 1 |
| Brittain, E | 1 |
| King, JT | 1 |
| Ho, YL | 1 |
| Eden, S | 1 |
| Kundu, S | 1 |
| Lann, MF | 1 |
| Greevy, RA | 1 |
| Ho, PM | 1 |
| Heidenreich, PA | 1 |
| Jacobson, DA | 1 |
| Douglas, IJ | 1 |
| Tate, JP | 1 |
| Evans, SJW | 1 |
| Atkins, D | 1 |
| Justice, AC | 1 |
| Freiberg, MS | 1 |
| Proietti, R | 1 |
| Stillson, JE | 1 |
| Bunch, CM | 1 |
| Gillespie, L | 1 |
| Khan, R | 1 |
| Wierman, M | 1 |
| Pulvirenti, J | 1 |
| Phyu, H | 1 |
| Anderson, S | 1 |
| Al-Fadhl, M | 1 |
| Thomas, AV | 1 |
| Kwaan, HC | 1 |
| Moore, E | 1 |
| Moore, H | 1 |
| Walsh, MM | 1 |
| Mennuni, MG | 1 |
| Renda, G | 1 |
| Grisafi, L | 1 |
| Rognoni, A | 1 |
| Colombo, C | 1 |
| Lio, V | 1 |
| Foglietta, M | 1 |
| Petrilli, I | 1 |
| Pirisi, M | 1 |
| Spinoni, E | 1 |
| Azzolina, D | 1 |
| Hayden, E | 1 |
| Aimaretti, G | 1 |
| Avanzi, GC | 1 |
| Bellan, M | 1 |
| Cantaluppi, V | 1 |
| Capponi, A | 1 |
| Castello, LM | 1 |
| Corte, FD | 1 |
| Gallina, S | 1 |
| Krengli, M | 1 |
| Malerba, M | 1 |
| Pierdomenico, SD | 1 |
| Savoia, P | 1 |
| Zeppegno, P | 1 |
| Sainaghi, PP | 1 |
| Patti, G | 1 |
| Kirkup, C | 1 |
| Pawlowski, C | 1 |
| Puranik, A | 1 |
| Conrad, I | 1 |
| O'Horo, JC | 1 |
| Gomaa, D | 1 |
| Banner-Goodspeed, VM | 1 |
| Mosier, JM | 1 |
| Zabolotskikh, IB | 1 |
| Daugherty, SK | 1 |
| Bernstein, MA | 1 |
| Zaren, HA | 1 |
| Bansal, V | 1 |
| Pickering, B | 1 |
| Badley, AD | 1 |
| Kashyap, R | 1 |
| Venkatakrishnan, AJ | 1 |
| Soundararajan, V | 1 |
| Myasnikov, AL | 1 |
| Berns, SA | 1 |
| Talyzin, PA | 1 |
| Ershov, FI | 1 |
| Jiménez-Soto, R | 1 |
| Aguilar-Soto, M | 1 |
| Rodríguez-Toledo, CA | 1 |
| Camiro-Zúñiga, A | 1 |
| Demichelis, R | 1 |
| Scarduelli, C | 1 |
| Inglese, F | 1 |
| Beccaria, M | 1 |
| Spreafico, F | 1 |
| Garuti, M | 1 |
| Pecoriello, A | 1 |
| Cervi, G | 1 |
| Greco, G | 1 |
| Scarduelli, S | 1 |
| Lucchini, G | 1 |
| De Donno, G | 1 |
| Borghi, C | 1 |
| Sezavar, SH | 2 |
| Moghadam, KG | 2 |
| Rahmani, H | 2 |
| Zoghi, E | 2 |
| Mohammadi, K | 2 |
| Abri, H | 2 |
| Tabrizi, S | 2 |
| Mousavian, SM | 2 |
| Rafiee, F | 2 |
| Baghizadeh, E | 2 |
| Aliannejad, R | 2 |
| Eslami, V | 2 |
| Kashefizadeh, A | 2 |
| Kakavand, H | 2 |
| Hosseini, SH | 2 |
| Shafaghi, S | 2 |
| Ghazi, SF | 2 |
| Najafi, A | 2 |
| Sethi, SS | 2 |
| Van Tassell, BW | 2 |
| Dobesh, PP | 2 |
| Fatimazahra, M | 1 |
| Harras, ME | 1 |
| Bensahi, I | 1 |
| Kassimi, M | 1 |
| Oualim, S | 1 |
| Elouarradi, A | 1 |
| Abdeladim, S | 1 |
| Sabry, M | 1 |
| Cohoon, K | 1 |
| Kittelson, JM | 1 |
| Hiatt, WR | 1 |
| Dale, RA | 1 |
| de Barros E Silva, PGM | 2 |
| Macedo, AVS | 2 |
| Ramacciotti, E | 2 |
| Damini, LP | 1 |
| Bronhara, B | 2 |
| Cavalcanti, AB | 2 |
| Rosa, RG | 2 |
| Azevedo, LCP | 2 |
| Veiga, VC | 2 |
| Machado, FR | 2 |
| Ritt, LE | 1 |
| Martins, PA | 1 |
| Alexander, JH | 2 |
| Avezum, A | 2 |
| Berwanger, O | 2 |
| Prats-Uribe, A | 1 |
| Sena, AG | 1 |
| Lai, LYH | 1 |
| Ahmed, WU | 1 |
| Alghoul, H | 1 |
| Alser, O | 1 |
| Alshammari, TM | 1 |
| Areia, C | 1 |
| Carter, W | 1 |
| Casajust, P | 1 |
| Dawoud, D | 1 |
| Golozar, A | 1 |
| Jonnagaddala, J | 1 |
| Mehta, PP | 1 |
| Gong, M | 1 |
| Morales, DR | 1 |
| Nyberg, F | 1 |
| Posada, JD | 1 |
| Recalde, M | 1 |
| Roel, E | 1 |
| Shah, K | 1 |
| Shah, NH | 1 |
| Schilling, LM | 1 |
| Subbian, V | 1 |
| Vizcaya, D | 1 |
| Zhang, L | 1 |
| Zhang, Y | 1 |
| Zhu, H | 1 |
| Liu, L | 1 |
| Cho, J | 1 |
| Lynch, KE | 1 |
| Matheny, ME | 1 |
| You, SC | 1 |
| Rijnbeek, PR | 1 |
| Hripcsak, G | 1 |
| Lane, JC | 1 |
| Burn, E | 1 |
| Reich, C | 1 |
| Suchard, MA | 1 |
| Duarte-Salles, T | 1 |
| Kostka, K | 1 |
| Ryan, PB | 1 |
| Prieto-Alhambra, D | 1 |
| Anastas, DC | 1 |
| Farias, A | 1 |
| Runyon, J | 1 |
| Laufer, M | 1 |
| Sendi, P | 1 |
| Totapally, B | 1 |
| Sachdeva, R | 1 |
| Pieralli, F | 1 |
| Pomero, F | 1 |
| Giampieri, M | 1 |
| Marcucci, R | 1 |
| Prisco, D | 1 |
| Luise, F | 1 |
| Mancini, A | 1 |
| Milia, A | 1 |
| Sammicheli, L | 1 |
| Tassinari, I | 1 |
| Caldi, F | 1 |
| Innocenti, F | 1 |
| Faraone, A | 1 |
| Beltrame, C | 1 |
| Pini, R | 1 |
| Ungar, A | 1 |
| Fortini, A | 1 |
| Damiani, LP | 1 |
| Barbosa, LM | 1 |
| de Aveiro Morata, J | 1 |
| de Aquino Martins, P | 1 |
| de Oliveira, AL | 1 |
| Nunes, VS | 1 |
| Ritt, LEF | 1 |
| Tramujas, L | 1 |
| Santos, SV | 1 |
| Diaz, DRA | 1 |
| Viana, LS | 1 |
| Melro, LMG | 1 |
| de Alcântara Chaud, MS | 1 |
| Figueiredo, EL | 1 |
| Neuenschwander, FC | 1 |
| Dracoulakis, MDA | 1 |
| Lima, RGSD | 1 |
| de Souza Dantas, VC | 1 |
| Fernandes, ACS | 1 |
| Gebara, OCE | 1 |
| Hernandes, ME | 1 |
| Queiroz, DAR | 1 |
| Canesin, MF | 1 |
| de Faria, LM | 1 |
| Feitosa-Filho, GS | 1 |
| Gazzana, MB | 1 |
| Liporace, IL | 1 |
| de Oliveira Twardowsky, A | 1 |
| Maia, LN | 1 |
| de Matos Soeiro, A | 1 |
| Conceição-Souza, GE | 1 |
| Armaganijan, L | 1 |
| Guimarães, PO | 1 |
| Casucci, G | 1 |
| Acanfora, D | 1 |
| Perepu, US | 1 |
| Chambers, I | 1 |
| Wahab, A | 1 |
| Ten Eyck, P | 1 |
| Wu, C | 1 |
| Dayal, S | 1 |
| Sutamtewagul, G | 1 |
| Bailey, SR | 1 |
| Rosenstein, LJ | 1 |
| Lentz, SR | 1 |
| Nadeem, R | 1 |
| Zufferey, PJ | 1 |
| Dupont, A | 1 |
| Lanoiselée, J | 1 |
| Bauters, A | 1 |
| Poissy, J | 1 |
| Goutay, J | 1 |
| Jean, L | 1 |
| Caplan, M | 1 |
| Levy, L | 1 |
| Susen, S | 1 |
| Delavenne, X | 1 |
| Abdelwahab, HW | 1 |
| Shaltout, SW | 1 |
| Sayed Ahmed, HA | 1 |
| Fouad, AM | 1 |
| Merrell, E | 1 |
| Riley, JB | 1 |
| Salama, R | 1 |
| Abdelrahman, AG | 1 |
| Darling, E | 1 |
| Fadel, G | 1 |
| Elfar, MSA | 1 |
| Sabry, K | 1 |
| Shah, J | 1 |
| Amin, H | 1 |
| Nieman, GF | 1 |
| Mishriky, A | 1 |
| Aiash, H | 1 |
| Antunes de Brito, CA | 1 |
| de Oliveira Filho, JRB | 1 |
| Marques, DT | 1 |
| Lencastre, MDC | 1 |
| de Almeida, JR | 1 |
| Lopes, EP | 1 |
| Salva, O | 1 |
| Alasino, R | 1 |
| Giller, C | 1 |
| Borello, J | 1 |
| Doresky, A | 1 |
| Karayan, G | 1 |
| Beltramo, D | 1 |
| Banda, NP | 1 |
| Hara, W | 1 |
| Cocker, D | 1 |
| Musasa, S | 1 |
| Burke, RM | 1 |
| Brown, C | 1 |
| Nyasulu, V | 1 |
| Mandalo, J | 1 |
| Tembo, D | 1 |
| Kachingwe, M | 1 |
| Cornick, J | 1 |
| Jambo, K | 1 |
| Morton, B | 1 |
| Escher, R | 1 |
| Breakey, N | 1 |
| Lämmle, B | 1 |
| Desborough, MJR | 1 |
| Doyle, AJ | 1 |
| Griffiths, A | 1 |
| Retter, A | 1 |
| Breen, KA | 1 |
| Hunt, BJ | 1 |
| Søvik, S | 1 |
| Bådstøløkken, PM | 1 |
| Sørensen, V | 1 |
| Myhre, PL | 1 |
| Prebensen, C | 1 |
| Omland, T | 1 |
| Berdal, JE | 1 |
| Jonmarker, S | 1 |
| Hollenberg, J | 1 |
| Dahlberg, M | 1 |
| Stackelberg, O | 1 |
| Litorell, J | 1 |
| Everhov, ÅH | 1 |
| Järnbert-Pettersson, H | 1 |
| Söderberg, M | 1 |
| Grip, J | 1 |
| Schandl, A | 1 |
| Günther, M | 1 |
| Cronhjort, M | 1 |
| Amerali, M | 1 |
| Politou, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ensayo clínico Aleatorizado, Abierto, Para Evaluar el Efecto de Dosis profilácticas o terapéuticas de Bemiparina en Pacientes Con COVID-19[NCT04604327] | Phase 3 | 164 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial)[NCT04401293] | Phase 3 | 257 participants (Actual) | Interventional | 2020-04-26 | Completed | ||
| FREEDOM COVID Anticoagulation Strategy Randomized Trial[NCT04512079] | Phase 4 | 3,460 participants (Actual) | Interventional | 2020-09-08 | Completed | ||
| COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial[NCT04354155] | Phase 2 | 40 participants (Actual) | Interventional | 2020-06-02 | Completed | ||
| Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus: The Multicenter Randomized Controlled Ovid Trial[NCT04400799] | Phase 3 | 475 participants (Actual) | Interventional | 2020-06-15 | Terminated (stopped due to due to results from interim analysis) | ||
| Early Thromboprophylaxis in COVID-19 (ETHIC Trial): an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care (no Enoxaparin) in COVID-19 Positive Patients[NCT04492254] | Phase 3 | 219 participants (Actual) | Interventional | 2020-10-27 | Terminated (stopped due to Average event rate (end point) was much lower than expected. A larger sample size would have been required to maintain same statistical power, which was not achievable in a feasible time scale. No safety concerns were identified with bleeding.) | ||
| The Role of Ischemia Modified Albumin in Patients With COVID-19[NCT05286268] | 194 participants (Anticipated) | Observational | 2022-04-06 | Recruiting | |||
| Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19[NCT04486508] | Phase 3 | 600 participants (Actual) | Interventional | 2020-07-30 | Completed | ||
| Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry and Validation of C2D2 (Critical Care Data Dictionary)[NCT04323787] | 100,000 participants (Anticipated) | Observational | 2020-03-30 | Recruiting | |||
| Prospective Two-week Open-label Application Experimental Randomized Single-center Non-interventional Study of the Drug Ingaron in Patients With a New Coronavirus Infection COVID-19[NCT05386459] | 36 participants (Actual) | Observational | 2020-04-21 | Completed | |||
| Evaluation of the Effect of Exogenous Surfactant Through Nebulizer Mask on Clinical Outcomes in Covid-19 Patients[NCT04847375] | 60 participants (Anticipated) | Interventional | 2021-04-20 | Not yet recruiting | |||
| Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial[NCT04394377] | Phase 4 | 615 participants (Actual) | Interventional | 2020-06-21 | Completed | ||
| Cellular Effects of SARS-CoV-2 in Mediating Thrombotic Susceptibility[NCT05334615] | 60 participants (Anticipated) | Observational | 2022-01-21 | Recruiting | |||
| Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial[NCT04466670] | Phase 2 | 379 participants (Anticipated) | Interventional | 2020-07-11 | Recruiting | ||
| Patient Characteristics, Outcome and Thromboembolic Events Among Adult Critically Ill COVID-19 Patients With Different Anticoagulant Regimes at One of the Biggest Emergency Hospitals in Northern Europe, Sweden[NCT04412304] | 166 participants (Actual) | Observational | 2020-03-06 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Risk of arterial thromboembolic events (including myocardial infarction, stroke, systemic embolism), venous thromboembolism (including symptomatic deep vein thrombosis (DVT) of the upper or lower extremity, asymptomatic proximal DVT of the lower extremity, non-fatal pulmonary embolism (PE)), and all-cause mortality at Day 30 ± 2 days. (NCT04401293)
Timeframe: Day 30 ± 2 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Full Dose LMWH Anticoagulation Therapy | 25 |
| Prophylactic/Intermediate Dose LMWH or UFH Therapy | 31 |
The composite of arterial thromboembolic events (including myocardial infarction, stroke, systemic embolism), venous thromboembolism (including symptomatic deep vein thrombosis (DVT) of the upper or lower extremity, asymptomatic proximal DVT of the lower extremity, non-fatal pulmonary embolism (PE)), and all-cause mortality at Hospital Day 10 + 4 (NCT04401293)
Timeframe: Day 10 + 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Full Dose LMWH Anticoagulation Therapy | 2 |
| Prophylactic/Intermediate Dose LMWH or UFH Therapy | 3 |
Risk of major bleeding defined using the International Society of Thrombosis and Haemostasis (ISTH) criteria (NCT04401293)
Timeframe: Day 30 ± 2 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Full Dose LMWH Anticoagulation Therapy | 6 |
| Prophylactic/Intermediate Dose LMWH or UFH Therapy | 2 |
Need for Intubation will be based on monitoring of patient conditions. (NCT04401293)
Timeframe: Day 30 ± 2 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Full Dose LMWH Anticoagulation Therapy | 17 |
| Prophylactic/Intermediate Dose LMWH or UFH Therapy | 21 |
Progression to Acute Respiratory Distress Syndrome (ARDS) based on monitoring of patient conditions. (NCT04401293)
Timeframe: Day 30 ± 2 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Full Dose LMWH Anticoagulation Therapy | 11 |
| Prophylactic/Intermediate Dose LMWH or UFH Therapy | 6 |
Need for Re-hospitalization will be based on monitoring of patient conditions. (NCT04401293)
Timeframe: Day 30 ± 2 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Full Dose LMWH Anticoagulation Therapy | 1 |
| Prophylactic/Intermediate Dose LMWH or UFH Therapy | 3 |
"Sepsis-induced coagulopathy (SIC) score predicts likelihood of sepsis-induced coagulopathy based on ISTH guidelines.~The score uses the following domains:~Platelets, K/uL (thousands per microliter)~INR (International Normalized Ratio)~D-Dimer Level~Fibrinogen~Platelet count > 100 cells x 10^9/L is 0 points, platelet count 50 to 100 cells x 10^9/L is 1 point and Platelet count < 50 cells x 10^9/L is 2 points. INR < 1.3 is 0 points, INR 1.3 to 1.7 is 1 point and INR > 1.7 is 2 points. D-Dimer level < 400 ng/mL is 0 points, D-Dimer level 400-4000 ng/mL is 2 points and D-Dimer level > 4000 ng/mL is 3 points. Fibrinogen level > 100 mg/dL is 0 points and fibrinogen level < 100 mg/dL is 1 point.~Calculated (SIC) scores yields a possible 0 to 6 points, where ≥4 predicts higher mortality rates within 30 days and greater risk of pulmonary embolism." (NCT04401293)
Timeframe: Day 30 ± 2 days.
| Intervention | units on a scale (Mean) |
|---|---|
| Full Dose LMWH Anticoagulation Therapy | 2.35 |
| Prophylactic/Intermediate Dose LMWH or UFH Therapy | 2.31 |
To investigate, on a preliminary basis, the efficacy of in-hospital thromboprophylaxis with twice-daily enoxaparin in children hospitalized with COVID-19, as measured by number of participants with confirmed HA-VTE. (NCT04354155)
Timeframe: Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Thromboprophylaxis | 2 |
"The safety of in-hospital thromboprophylaxis with twice-daily low-dose enoxaparin thromboprophylaxis will be measured by cumulative incidence (number of participants) of ISTH-defined clinically-relevant bleeding events during hospitalization. Clinically relevant bleeding episodes may include any of the following:~fatal bleeding;~clinically overt bleeding associated with a decline in hemoglobin of ≥2g/dL in a 24h period;~retroperitoneal, pulmonary, or central nervous system bleeding;~bleeding requiring surgical intervention in an operating suite;~bleeding for which a blood product is administered (blood product administration not directly attributable to the patient's underlying condition);~bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating suite." (NCT04354155)
Timeframe: Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Thromboprophylaxis | 0 |
The median twice-daily enoxaparin dose, as measured in mg/kg, required to achieve a 4-hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL in children hospitalized with COVID-19, and to compare dose-requirements by age group (<12 and those >12 years of age). (NCT04354155)
Timeframe: 4 hours post initial dose
| Intervention | mg/kg (Median) | |
|---|---|---|
| Children 12 years or older | Children less than 12 years | |
| Thromboprophylaxis | 0.5 | 0.52 |
8 reviews available for dalteparin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies.
Topics: Acute Kidney Injury; Aldosterone; Angiotensins; Antibodies, Monoclonal, Humanized; Autopsy; Biopsy; | 2022 |
Heparin and SARS-CoV-2: Multiple Pathophysiological Links.
Topics: Anticoagulants; COVID-19; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Heparin, Low-Molecular-Weig | 2021 |
Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.
Topics: Anticoagulants; COVID-19; Critical Care; Enoxaparin; Hospitalization; Humans; Pyrazoles; Pyridones; | 2022 |
Enoxaparin for COVID-19: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; Randomized Controlled Trials as Topic; Venous Thromboe | 2023 |
Scientific considerations in the regulatory approval of generic (or biosimilar) version of enoxaparin sodium - A lifesaving carbohydrate polymer.
Topics: Animals; Biosimilar Pharmaceuticals; COVID-19; Drug Approval; Drugs, Generic; Enoxaparin; Humans; Ph | 2023 |
Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antirheumatic Agents; Betacoronavirus; Coronaviru | 2020 |
Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and literature review.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Combined | 2020 |
Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses.
Topics: Aged; Anticoagulants; COVID-19; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Pregnancy; T | 2022 |
22 trials available for dalteparin and 2019 Novel Coronavirus Disease
108 other studies available for dalteparin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury.
Topics: Acute Kidney Injury; Anticoagulants; COVID-19; Critical Illness; Humans; Nadroparin; Prospective Stu | 2022 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19.
Topics: Anticoagulants; COVID-19; Humans; Nadroparin | 2023 |
Arterial and venous thromboembolic disease in a patient with COVID-19: A case report.
Topics: Anticoagulants; Cerebral Infarction; Clopidogrel; Computed Tomography Angiography; Coronavirus Infec | 2020 |
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection.
Topics: Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Blood Coagulation; COVID-19; COVID-19 Drug Trea | 2020 |
Efficacy and safety of therapeutic vs. prophylactic bemiparin in noncritically ill patients with COVID-19 pneumonia.
Topics: Anticoagulants; COVID-19; Heparin, Low-Molecular-Weight; Humans | 2022 |
[Incidence of heparin-induced thrombocytopenia in patients with 2019 coronavirus disease].
Topics: Aged; Aged, 80 and over; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Female; | 2020 |
Effect of adding bemiparin and cefepime to routine treatment in cancer patients with SARS-CoV-2 infection.
Topics: Cefepime; COVID-19; Heparin, Low-Molecular-Weight; Humans; Neoplasms; SARS-CoV-2 | 2021 |
Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave versus the second wave.
Topics: Aged; Amides; Antibodies, Monoclonal, Humanized; Azithromycin; C-Reactive Protein; Comorbidity; COVI | 2022 |
Incidence and effects of deep vein thrombosis on the outcome of patients with coronavirus disease 2019 infection.
Topics: Adult; Aged; Anticoagulants; COVID-19; Enoxaparin; Female; Humans; Incidence; Male; Middle Aged; Pul | 2022 |
An AGEP case due to COVİD-19 or favipiravir or enoxaparin.
Topics: Amides; COVID-19; Enoxaparin; Humans; Pyrazines; SARS-CoV-2 | 2022 |
Enoxaparin dose impacts blood cell phenotypes during mild SARS-CoV-2 infection: the observational single-center study.
Topics: Anticoagulants; Blood Platelets; COVID-19; Enoxaparin; Humans; Phenotype; Retrospective Studies; SAR | 2021 |
Arteritic Anterior Ischemic Optic Neuropathy in the Course of Giant Cell Arteritis After COVID-19.
Topics: Aged; COVID-19; Enoxaparin; Female; Giant Cell Arteritis; Humans; Optic Neuropathy, Ischemic; SARS-C | 2022 |
A Patient-Tailored Approach to Management of Acute Limb Ischemia in Patients with COVID-19: A Case Series.
Topics: Adult; Aged; Arterial Occlusive Diseases; COVID-19; Enoxaparin; Female; Humans; Ischemia; Male; Midd | 2022 |
Case of Venous Thromboembolia Under Enoxaparin Prophylaxis After Recovering From Acute Ischemic Stroke in Consequence of COVID-19-Related MIS-C.
Topics: Anticoagulants; Brain Ischemia; COVID-19; Enoxaparin; Humans; Ischemic Stroke; Systemic Inflammatory | 2022 |
Identification of Kukoamine A, Zeaxanthin, and Clexane as New Furin Inhibitors.
Topics: Amino Acid Chloromethyl Ketones; Catalytic Domain; Cell Line, Tumor; Cell Survival; COVID-19; Enoxap | 2022 |
The role of heparin in reducing in-hospital complications and three-month mortality rates in hospitalized COVID-19 patients.
Topics: Anticoagulants; COVID-19; Enoxaparin; Heparin; Hospitals; Humans | 2022 |
[Deep venous thrombosis incidence in patients with COVID-19 acute respiratory distress syndrome, under intermediate dose of chemical thromboprophylaxis].
Topics: Anticoagulants; COVID-19; Cross-Sectional Studies; Enoxaparin; Humans; Incidence; Respiratory Distre | 2022 |
Retroperitoneal hematoma in COVID-19 patients - case series.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; COVID-19; Enoxaparin; Female; Hematoma; Heparin, Low | 2022 |
[Comment on article "Enoxaparin dose associated with decreased risk of death in COVID-19"].
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans | 2022 |
Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies?
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; COVID-19; Enoxaparin; Humans; Manni | 2022 |
Thromboprophylaxis and clinical outcomes in moderate COVID-19 patients: A comparative study.
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; Rivaroxaban; Venous Thromboembolism | 2022 |
Advanced cell therapy with low tissue factor loaded product NestaCell® does not confer thrombogenic risk for critically ill COVID-19 heparin-treated patients.
Topics: Cell- and Tissue-Based Therapy; Clinical Trials as Topic; COVID-19; Critical Illness; Enoxaparin; He | 2022 |
Is Rivaroxaban Superior to Enoxaparin for Thromboprophylaxis in Hospitalized Patients of COVID-19?`.
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; Rivaroxaban; Venous Thromboembolism | 2022 |
The Role of Disordered Regions in Orchestrating the Properties of Multidomain Proteins: The SARS-CoV-2 Nucleocapsid Protein and Its Interaction with Enoxaparin.
Topics: COVID-19; Enoxaparin; Humans; Nucleocapsid Proteins; Polyelectrolytes; RNA; SARS-CoV-2 | 2022 |
Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case Report.
Topics: Adult; Angiogenesis Inhibitors; COVID-19; COVID-19 Serotherapy; Enoxaparin; Glucocorticoids; Humans; | 2022 |
Inhalation of Low Molecular Weight Heparins as Prophylaxis against SARS-CoV-2.
Topics: COVID-19; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; SARS-CoV-2 | 2022 |
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS- | 2022 |
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS- | 2022 |
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS- | 2022 |
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS- | 2022 |
The Effectiveness of the Intermediate and Therapeutic Doses of Enoxaparin in COVID-19 Patients: A Comparative Study of Factor Xa Inhibition.
Topics: Anticoagulants; COVID-19; Cross-Sectional Studies; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Hepa | 2023 |
HIGH HEPARANASE LEVEL IN SURVIVORS OF COVID-19 - INDICATOR OF VASCULAR AND PULMONARY RECOVERY?
Topics: Cohort Studies; COVID-19; COVID-19 Drug Treatment; Endothelium, Vascular; Enoxaparin; Glucuronidase; | 2022 |
External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial.
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; Risk Assessment; Risk Factors; Venous Thromboembolism; | 2023 |
Acute Mesenteric Ischemia in COVID-19 While Receiving Prophylactic Enoxaparin.
Topics: Anticoagulants; COVID-19; Enoxaparin; Female; Humans; Mesenteric Ischemia; Treatment Outcome | 2022 |
Enoxaparin's potential mechanisms against SARS-CoV-2.
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; SARS-CoV-2 | 2023 |
Clinical experience of prophylactic enoxaparin dosage adjustment guided by AntiXa factor levels in critical care patients with COVID-19-induced pneumonia: observational study.
Topics: Anticoagulants; COVID-19; Critical Care; Enoxaparin; Heparin, Low-Molecular-Weight; Humans | 2023 |
Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease.
Topics: Acute Disease; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Betacoronavirus; Biomarkers; | 2020 |
COVID-19 and Acute Pulmonary Embolism in Postpartum Patient.
Topics: Acute Disease; Adult; Anticoagulants; Betacoronavirus; Cesarean Section; Clinical Laboratory Techniq | 2020 |
Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.
Topics: Aged; Anticoagulants; Coronavirus Infections; COVID-19; Enoxaparin; Female; Fibrin Fibrinogen Degrad | 2020 |
Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.
Topics: Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Enoxaparin; Hemostasis; Humans; I | 2020 |
Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".
Topics: Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Enoxaparin; Humans; Pandemics; Pn | 2020 |
Cerebral Infarction in an Elderly Patient with Coronavirus Disease.
Topics: Aged, 80 and over; Anticoagulants; Aspirin; Betacoronavirus; Cerebral Infarction; Coronavirus; Coron | 2020 |
Pulmonary embolism: A complication of COVID 19 infection.
Topics: Adult; Aged; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Enoxaparin; Female; | 2020 |
Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin.
Topics: Aged; Anti-Inflammatory Agents; Anticoagulants; Antihypertensive Agents; Azithromycin; Combined Moda | 2020 |
Heart transplant recipient patient with COVID-19 treated with tocilizumab.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Cardiomyopathy, Dilated; C | 2020 |
Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Azithromycin; Betaco | 2020 |
Large artery ischemic stroke in severe COVID-19.
Topics: Aged; Brain Ischemia; Cerebral Arteries; Computed Tomography Angiography; Coronavirus Infections; CO | 2020 |
Acute Portal Vein Thrombosis in SARS-CoV-2 Infection: A Case Report.
Topics: Acute Disease; Aged; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Enoxaparin; | 2020 |
Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis.
Topics: Aged; Aged, 80 and over; COVID-19; Enoxaparin; Female; Fondaparinux; Guidelines as Topic; Hospitaliz | 2020 |
Covid-19: A systemic disease treated with a wide-ranging approach: A case report.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Azithromycin; China; Coronavirus Infecti | 2020 |
How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report.
Topics: Aged; Betacoronavirus; Blood Coagulation; Coronavirus Infections; COVID-19; Enoxaparin; Female; Fibr | 2020 |
Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban.
Topics: Arterial Occlusive Diseases; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatm | 2020 |
Venous thromboembolism in non-critically ill patients with COVID-19 infection.
Topics: Aged; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Enoxaparin; Female; Fondapa | 2020 |
VTE in ICU Patients With COVID-19.
Topics: Adult; Aged; Anticoagulants; Betacoronavirus; C-Reactive Protein; Computed Tomography Angiography; C | 2020 |
Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease.
Topics: Acute Disease; Aged; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Disease Prog | 2020 |
A Case of 45-Year Man Who Succumbed to Coronavirus Disease 2019 (COVID-19).
Topics: Anti-Bacterial Agents; Anticoagulants; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus; | 2020 |
COVID-19 Pulmonary Infection with Pneumothorax in a Young Patient.
Topics: Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus; | 2020 |
A Rare Finding of Upper Limb Deep Venous Thrombosis in a Patient with COVID-19.
Topics: Anticoagulants; Arm; Aspirin; Betacoronavirus; Coronavirus Infections; COVID-19; Edema; Enoxaparin; | 2020 |
Priapism in a patient with coronavirus disease 2019 (COVID-19).
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; Male; Middle Aged; Priapism; Thrombosis | 2021 |
Saddle pulmonary embolism and thrombus-in-transit straddling the patent foramen ovale 28 days after COVID symptom onset.
Topics: Aged; Anticoagulants; Computed Tomography Angiography; COVID-19; Dyspnea; Echocardiography; Enoxapar | 2020 |
Use of awake proning to avoid invasive ventilation in a patient with severe COVID-19 pneumonitis.
Topics: Anticoagulants; Betacoronavirus; Chemoprevention; Computed Tomography Angiography; Coronavirus Infec | 2020 |
COVID-19 associated with extensive pulmonary arterial, intracardiac and peripheral arterial thrombosis.
Topics: Anticoagulants; Betacoronavirus; Clinical Deterioration; Computed Tomography Angiography; Coronaviru | 2020 |
COVID-19 patient with immune thrombocytopenic purpura.
Topics: Aged, 80 and over; Anticoagulants; Autoantibodies; Betacoronavirus; Combined Modality Therapy; Coron | 2020 |
Safety of intermediate dose of low molecular weight heparin in COVID-19 patients.
Topics: Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Female; Follow-Up Studies; H | 2021 |
COVID-19 in a pediatric patient with Glanzmann thrombasthenia.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; C-Reactive Protein; Computed Tomography Angiography; | 2020 |
An infection-oriented approach for thoracic endovascular aortic repair in a SARS-CoV-2 positive patient. A case report.
Topics: Anesthesia, Local; Antibiotic Prophylaxis; Anticoagulants; Antiviral Agents; Aortic Aneurysm, Thorac | 2020 |
Rotational thromboelastometry in young, previously healthy patients with SARS-Cov2.
Topics: Adult; Anticoagulants; Blood Coagulation Disorders; COVID-19; Enoxaparin; Heparin; Humans; Pyrazoles | 2020 |
Inferior mesenteric vein thrombosis and COVID-19.
Topics: Adult; Analgesics; Anticoagulants; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; E | 2020 |
The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin.
Topics: Aged; Aged, 80 and over; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Factor Xa In | 2020 |
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.
Topics: Adolescent; Adult; Asymptomatic Diseases; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatme | 2020 |
Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience.
Topics: Aged; Anticoagulants; Antithrombins; Coronavirus Infections; COVID-19; Enoxaparin; Factor Xa Inhibit | 2020 |
Thrombo-prophylaxis prevents thrombotic events in home-managed COVID patients. A registry study.
Topics: Aged; Anticoagulants; Body Mass Index; Case-Control Studies; COVID-19; Enoxaparin; Female; Heparin, | 2020 |
The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Clinical Protocols; COVID-19; Critical Care; Critica | 2021 |
Venous thromboembolism and COVID-19: a case report and review of the literature.
Topics: Aged; Anticoagulants; Betacoronavirus; Computed Tomography Angiography; Coronavirus Infections; COVI | 2020 |
Treatment of COVID-19 induced chilblains with topical nitroglycerin.
Topics: Administration, Cutaneous; Anticoagulants; Betacoronavirus; Chilblains; Coronavirus Infections; COVI | 2020 |
Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease.
Topics: Ampicillin; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; Azithromycin; Child; COVID-19; | 2021 |
Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization.
Topics: Aged; Aged, 80 and over; Anticoagulants; C-Reactive Protein; Cognition Disorders; Cohort Studies; Co | 2021 |
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality.
Topics: Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Blood Coagulation; Cohort Studies; COVID-19; CO | 2020 |
Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Cardiovascular Diseases; Comorbidity; COV | 2020 |
The unusual experience of managing a severe COVID-19 case at home: what can we do and where do we go?
Topics: Adrenal Cortex Hormones; Ambulatory Care; Antiparasitic Agents; Betacoronavirus; Coronavirus Infecti | 2020 |
A case of Evans syndrome secondary to COVID-19.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Anticoagulants; COVID-19; Enoxaparin; Humans; Immunoglobulins, | 2021 |
Antiphospholipid antibodies in patients with coronavirus disease 2019 infection hospitalized in conventional unit.
Topics: Aged; Aged, 80 and over; Antibodies, Antiphospholipid; Anticoagulants; COVID-19; COVID-19 Drug Treat | 2021 |
Thromboelastography clot strength profiles and effect of systemic anticoagulation in COVID-19 acute respiratory distress syndrome: a prospective, observational study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Blood Coagulation Disorders; Blood Coagulati | 2020 |
Superficial Cerebral Venous Thrombosis and Intracerebral Hematoma in a 48-Year-Old Man with SARS-CoV-2 Infection: A Case Report.
Topics: Anticoagulants; Cerebral Hemorrhage; COVID-19; Enoxaparin; Hematoma; Humans; Intracranial Thrombosis | 2021 |
Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19.
Topics: Aged; Body Mass Index; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Female; Hepari | 2021 |
Prolonged treatment of COVID-19 pneumonia with high-flow nasal oxygen: A story of oxygen and resilience.
Topics: Anti-Bacterial Agents; Anticoagulants; Anxiety; Blood Gas Analysis; Cannula; Citalopram; Counseling; | 2020 |
Efficacy and Safety of D-dimer, Weight, and Renal Function-Adjusted Thromboprophylaxis in Patients with Coronavirus Disease 2019 (COVID-19).
Topics: Aged; Aged, 80 and over; Anticoagulants; Body Weight; C-Reactive Protein; COVID-19; Dose-Response Re | 2021 |
Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus.
Topics: Antiviral Agents; Child, Preschool; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cy | 2021 |
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.
Topics: Anticoagulants; COVID-19; Enoxaparin; Evidence-Based Medicine; Guidelines as Topic; Humans; SARS-CoV | 2021 |
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; COVID-19; Enoxaparin; Female; Hemorrhage; Humans; Ma | 2021 |
Fondaparinux and bleeding risk in COVID-19: unsolved question.
Topics: Anticoagulants; COVID-19; Enoxaparin; Fondaparinux; Humans; Retrospective Studies; SARS-CoV-2 | 2021 |
Thromboelastography-Guided Management of Anticoagulated COVID-19 Patients to Prevent Hemorrhage.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anticoagulants; Blood Coagulation Tests; Blood Proteins; | 2021 |
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19.
Topics: Aged; Aged, 80 and over; Anticoagulants; COVID-19; Enoxaparin; Female; Hospital Mortality; Hospitali | 2021 |
Healthcare disparities among anticoagulation therapies for severe COVID-19 patients in the multi-site VIRUS registry.
Topics: Anticoagulants; Blood Coagulation; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Female; Healthcare | 2021 |
The impact of different prophylactic anticoagulation doses on the outcomes of patients with COVID-19.
Topics: Anticoagulants; Blood Coagulation; COVID-19; Enoxaparin; Humans; SARS-CoV-2 | 2021 |
Pulmonary embolism in patients with severe COVID-19 treated with intermediate- to full-dose enoxaparin: A retrospective study.
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; Pulmonary Embolism; Retrospective Studies; SARS-CoV-2; | 2021 |
Ovarian vein thrombosis after coronavirus disease (COVID-19) mimicking acute abdomen: two case reports.
Topics: Abdomen, Acute; Adult; Anticoagulants; COVID-19; Diagnosis, Differential; Enoxaparin; Female; Fibrin | 2021 |
Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.
Topics: Administrative Claims, Healthcare; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and ov | 2021 |
Massive Pulmonary Embolism in an Adolescent With Multisystem Inflammatory Syndrome Due to COVID-19.
Topics: Adolescent; Computed Tomography Angiography; COVID-19; Enoxaparin; Female; Fibrinolytic Agents; Huma | 2021 |
Incidence of deep vein thrombosis through an ultrasound surveillance protocol in patients with COVID-19 pneumonia in non-ICU setting: A multicenter prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; COVID-19; Enoxaparin; Female; Fondaparinux; Humans; Inciden | 2021 |
DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination.
Topics: ChAdOx1 nCoV-19; Clinical Laboratory Techniques; COVID-19; COVID-19 Vaccines; Dexamethasone; Dissemi | 2021 |
High-Dose Prophylactic Anticoagulation in Severe COVID-19 Pneumonia.
Topics: Anticoagulants; Blood Coagulation; COVID-19; Enoxaparin; Humans; SARS-CoV-2 | 2021 |
Pharmacokinetics of enoxaparin in COVID-19 critically ill patients.
Topics: Anticoagulants; COVID-19; Critical Illness; Enoxaparin; Humans; Retrospective Studies; SARS-CoV-2 | 2021 |
Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study.
Topics: Anticoagulants; Aspirin; COVID-19; Enoxaparin; Humans; Respiration, Artificial; Retrospective Studie | 2021 |
COVID-19 and Hepatic Artery Thrombosis: A Case Report.
Topics: COVID-19; Enoxaparin; Female; Hepatic Artery; Humans; Middle Aged; SARS-CoV-2; Thrombosis | 2021 |
First case report of a successfully managed severe COVID-19 infection in Malawi.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Anticoagulants; Ceftriaxone; COVID-19; COVID-19 | 2020 |
Severe COVID-19 infection associated with endothelial activation.
Topics: Aged; Antibodies, Antiphospholipid; Anticoagulants; Betacoronavirus; Blood Coagulation; Coronavirus | 2020 |
Severe COVID-19 infection associated with endothelial activation.
Topics: Aged; Antibodies, Antiphospholipid; Anticoagulants; Betacoronavirus; Blood Coagulation; Coronavirus | 2020 |
Severe COVID-19 infection associated with endothelial activation.
Topics: Aged; Antibodies, Antiphospholipid; Anticoagulants; Betacoronavirus; Blood Coagulation; Coronavirus | 2020 |
Severe COVID-19 infection associated with endothelial activation.
Topics: Aged; Antibodies, Antiphospholipid; Anticoagulants; Betacoronavirus; Blood Coagulation; Coronavirus | 2020 |
Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; C | 2020 |
A single-centre, prospective cohort study of COVID-19 patients admitted to ICU for mechanical ventilatory support.
Topics: Anticoagulants; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Critical Care; Dalteparin; Female | 2021 |
Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.
Topics: Aged; Anticoagulants; APACHE; COVID-19; Critical Illness; Dalteparin; Female; Humans; Intensive Care | 2020 |